OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Duska on the Utility of the Fagotti Score in Advanced Ovarian Cancer

January 29th 2020

Linda R. Duska, MD, professor of obstetrics and gynecology and gynecologic oncologist at the University of Virginia, explains whether the Fagotti score provides an accurate assessment of whether a patient with newly diagnosed, advanced ovarian cancer can achieve a complete resection in surgery.

Dr. Bahlis on Daratumumab Plus Lenalidomide and Dexamethasone in Multiple Myeloma

January 29th 2020

Nizar J. Bahlis, MD, discusses daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone in newly diagnosed multiple myeloma.

Dr. Cowan on Efficacy and Safety of BCMA CAR T-Cells in Multiple Myeloma

January 29th 2020

Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr. Borghaei on Immunotherapy versus Chemotherapy and Immunotherapy in NSCLC

January 29th 2020

Hossein Borghaei, DO, MS, discusses immunotherapy alone or in combination with chemotherapy in combination with immunotherapy in patients with advanced NSCLC.

Dr. Kremyanskaya on Effect of CPI-0610 in Patients With Myelofibrosis

January 29th 2020

Marina Kremyanskaya, MD, discusses the effect of CPI-0610 in patients with myelofibrosis.

Dr. Martin on Biomarker-Driven Therapeutics in Multiple Myeloma

January 29th 2020

Thomas G. Martin, MD, discusses biomarker-driven treatment options in multiple myeloma and currently available regimens.

Dr. Nasri on the Role of p16 and p21 as Predictive Biomarkers in Osteosarcoma

January 29th 2020

Elham Nasri, MD, discusses the role of p16 and p21 as predictive biomarkers in patients with osteosarcoma.

Dr. Aboulafia on Targeted Therapy in Tenosynovial Giant Cell Tumor

January 29th 2020

Albert J. Aboulafia, MD, discusses targeted therapy options in tenosynovial giant cell tumor.

Dr. Koo on the Actionability of Next-Generation Imaging Results in Prostate Cancer

January 29th 2020

Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, discusses the actionability of next-generation imaging results in prostate cancer.

Dr. Bryce on Ongoing Research in Prostate Cancer

January 29th 2020

Alan H. Bryce, MD, assistant professor of medicine and medical director of the Genomic Oncology Clinic, Mayo Clinic, discusses ongoing research in prostate cancer.

Dr. Hwang on the State of Treatment in Metastatic Prostate Cancer

January 29th 2020

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the state of treatment in metastatic prostate cancer.

Dr. Taylor on Molecular Testing Recommendations in Ovarian Cancer

January 29th 2020

Sarah E. Taylor, MD, discusses molecular testing recommendations in ovarian cancer.

Dr. Fowler on Selection Criteria for Surgical Procedures in Ovarian Cancer

January 29th 2020

Jeffrey M. Fowler, MD, discusses selection criteria that can help determine which surgical procedure to pursue in ovarian cancer.

Dr. Boisen on Neoadjuvant Chemotherapy Versus Upfront Surgery in Ovarian Cancer

January 29th 2020

Michelle M. Boisen, MD, discusses the selection of neoadjuvant chemotherapy versus upfront surgery for women with newly diagnosed ovarian cancer.

Dr. Mesa on JAK Inhibitors in the Pipeline for Myelofibrosis

January 28th 2020

Ruben A. Mesa, MD, discusses the approval of fedratinib in myelofibrosis and other JAK inhibitors in the treatment pipeline.

Dr. Gerds on Addressing Anemia in Myelofibrosis

January 28th 2020

Aaron Gerds, MD, discusses the adverse event anemia in patients with myelofibrosis.

Dr. Dunavin on Ongoing Research for Myelofibrosis Treatments

January 28th 2020

Neil Dunavin, MD, MS, discusses ongoing research on therapies for patients with myelofibrosis.

Dr. Bauml on the Utility of Liquid Biopsy in Metastatic NSCLC

January 28th 2020

Joshua Bauml, MD, discusses the utility of liquid biopsy in metastatic non–small cell lung cancer.

Dr. Shah on Daratumumab-Based Regimens in Frontline Multiple Myeloma

January 28th 2020

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses daratumumab (Darzalex)-based regimens in the frontline treatment of patients with multiple myeloma.

Dr. Vusirikala on Ongoing Research With Blinatumomab in ALL

January 28th 2020

Madhuri Vusirikala, MD, professor of internal medicine in the Division of Hematology/Oncology at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center, discusses ongoing research with blinatumomab (Blincyto) in acute lymphoblastic leukemia (ALL).